14 Feb 2021: Researchers at the Cleveland Clinic found that zinc or ascorbic acid (vitamin C) or a combination of both did not significantly reduce the severity or duration of symptoms in COVID-19-positive patients compared to standard care.
The research was published today on the JAMA Open Network. Since the beginning of the COVID-19 pandemic, people have made extensive speculations about the role of various vitamins and their supplements in prevention or treatment, but scientific evidence is still limited. It is known that zinc is important for immune function. It also plays a role in the production of antibodies and white blood cells and can fight infections.
Vitamin C, an antioxidant, can help reduce damage to cells and has the effect of enhancing immunity. The COVIDAtoZ clinical trial recruited 214 adult patients with confirmed COVID-19 infection. The patients were randomly assigned and received 10 days of zinc gluconate (50 mg), vitamin C (8000 mg), two drugs, or standard treatment from April 2020 to October 2020.
The study was discontinued due to invalidity, and there was no significant difference between the two groups. Four groups. Specifically, the endpoint of 50% reduction in symptoms showed no significant difference between conventional care, vitamin C, zinc gluconate, or groups receiving both vitamin C and zinc gluconate.
“When we started the trial, there was no research to support complementary therapies to prevent or treat COVID-19 patients,” said Milind Desai, Ph.D. MBA from the Cleveland Clinic Cardiovascular and Thoracic Disease Institute and Cooperative Medicine Division-the main investigator of the study.
“When we see the pandemic spreading globally, infecting and killing millions of people, the medical community and consumers are scrambling to try supplements. They think these supplements can prevent infection or alleviate the symptoms of COVID-19, but these studies are catching up. Although vitamin C and zinc are clinically proven to be ineffective compared to standard care, research on other therapies continues.
” The patients in this study were not hospitalized but were treated in an outpatient clinic. “We know that not all COVID-19 patients need to be hospitalized, and compared to patients treated in hospitals, they are more likely to look for supplements that can help them, so this is an important research population,” MD, MBA, Vice Chairman of Strategic Business of the Cleveland Clinic’s Cardiothoracic and Vascular Institute, and co-leader of the study Suma Thomas (Suma Thomas) said.
A total of 4 safety events were observed during the trial, including 3 deaths, but the Data Security Monitoring Committee did not believe that any adverse events were caused by the individual treatment that the patients received as part of the study. People can take some measures to reduce the risk of infection.
If possible, get the COVID-19 vaccine. Continue to maintain social distancing, wash your hands frequently, and wear a mask in public.